Israel Cancer Research Fund (ICRF)

Israel Cancer Research Fund (ICRF) is a nonprofit organization founded in 1975 by Dr. Daniel G. Miller and a group of American and Canadian physicians, scientists, and philanthropists to prevent Israel’s talented young scientists from leaving the country due to a lack of research funding. Today, ICRF is the largest nongovernmental funder of early-stage cancer research in Israel, having invested more than $100 million through thousands of grants to scientists at leading academic and medical institutions across the country.

ICRF’s grantmaking process is overseen by a volunteer Scientific Review Panel of leading physicians and scientists from major research institutions throughout North America, ensuring awards are made purely on scientific merit. Notably, ICRF awards are given directly to researchers without any institutional overhead deduction, meaning donor dollars go entirely toward funding the science. ICRF-funded scientists have contributed to the development of breakthrough FDA-approved cancer drugs, including Gleevec, Doxil, and Velcade, and count among their ranks the first two Israeli Nobel Prize Laureates in Chemistry.

Headquartered in New York City, ICRF operates active chapters across the United States, Canada, and Israel, engaging donors and volunteers through local fundraising events, campaigns, and educational programming in support of its mission to end the suffering caused by cancer.